Description

ICON plc Partners With Anthropic And Microsoft To Reshape Clinical Trials With AI!

ICON plc reported second quarter 2026 results characterized by modest revenue growth, strong bookings, and continued investment in strategic capabilities, amid mixed margin pressures largely influenced by pass-through activity. Total revenue increased 1.2% year-over-year to $2.1 billion, with adjusted EBITDA reaching $327 million and adjusted earnings per share of $2.56. These results aligned with company expectations for sequential earnings progression, though higher-than-anticipated pass-through costs diluted gross margins and impacted overall margin percentages. Bookings remained robust, with gross business wins of $3.7 billion—up 24% year-over-year and 13% sequentially—and net bookings of $3.1 billion, translating to a net book-to-bill ratio of 1.51x. This strong demand was broadly distributed across customer segments, including large pharma, midsized companies, and biotech firms. Notably, biotech segment engagement increased during the quarter, reflected in heightened RFP flow and new partnerships, although it brought a higher proportion of preliminary proposals (“ballpark” bids) with lower conversion rates.